Clinical Trial Update: An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy [Phase 2]

View source ↗

Summary

An open-label extension study evaluating the safety and effectiveness of RWJ 333369 in epilepsy has completed Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial Epilepsy

Drugs mentioned

• RWJ 333369 (RWJ-333369)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Epilepsy, Epilepsies, Partial | Phase 2 | Status: COMPLETED